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SynaptosomesEmerging evidence from therapeutic trials in humans and animal models suggests that in the treatment of
depression, antidepressants play a role by targeting the glutamatergic system. Fluvoxamine is one of the
widely used SSRIs which has been considered to target monoamine neurotransmitter reuptake mechanisms.
However, whether ﬂuvoxamine has an effect on the glutamate release is still unclear. The present experiment
studied the effect of ﬂuvoxamine on presynaptic glutamate release in prelimbic cortex, both in control C57BL/
6 mice and chronic restraint stress C57BL/6 mice, and further investigated the mechanism underlying this ef-
fect by using patch clamp, on-line ﬂuorimetry, pharmacological approaches combined with other techniques.
The results showed that ﬂuvoxamine increased the glutamate release in the depression model mice but it had
no effect on the glutamate release in the control mice. The mechanism underlying these effects in depression
model mice was that, ﬂuvoxamine ﬁrstly activated presynaptic 5-HT3 receptors, which transiently increased
the Ca2+ concentration. The increase of Ca2+ concentration via 5-HT3 receptors caused the activation of
sigma-1 receptors, which were activated by ﬂuvoxamine. The activation of sigma-1 receptors increased the
intrasynaptosomal Ca2+ concentration signiﬁcantly through the outﬂow of endoplasmic reticulum calcium
and ﬁnally activated PKC. These results suggested that ﬂuvoxamine may have a selective effect and different
mechanism based on the condition of animal.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Although depression has been studied for many years, the
neurobiological basis is still not very clear. It is generally accepted that
the decrease ofmonoamine in synaptic gapmay be an importantmech-
anism underlying the pathophysiology of depression. Apart from a
monoaminergic theory of depression,multiple lines of evidence suggest
that depressionmay involvemany non-monoamine basedmechanisms
which include glutamatergic system [1–4], hypothalamic-pituitary-
adrenal (HPA) axis [5,6], the neurokinin system [7], brain-derived
neurotrophic factor (BDNF) and other mechanisms [8]. However,
most currently available antidepressants target monoamine neuro-
transmitter reuptake mechanisms by inhibiting the 5-HT or NE trans-
porters in presynaptic membrane which are known as selective
serotonin reuptake inhibitor (SSRI) and/or norepinephrine reuptake in-
hibitor (SNRI). The emerging evidence suggests that many SSRI/SNRI
antidepressants produce their effects not only by inhibiting the reup-
take of 5-HT/NE but also by other mechanisms. It has been reported
that some antidepressants such as tianeptine may elicit their clinicalMedical Neurobiology, Fudan
oad, Shanghai, 200032, China.
l rights reserved.effects by modulation of glutamatergic neurotransmission in the rat
amygdala [9]. There are also some indications that monoamine-based
antidepressants promote AMPA receptor function [10]. Some
monoamine-based antidepressants also regulate NMDA receptors or in-
ﬂuence glutamate release through presynaptic mechanisms [11–13].
Based on these observations, the mechanisms of SSRIs may involve
many neurotransmitters and receptors besides monoamine system,
which may be consistent with the non-monoamine based mechanisms
of depression. Thus, the possible mechanism of SSRIs based on the non-
monoamine based mechanisms of depression needs to be studied.
However, the precise cellular mechanisms underlying the inﬂuence of
SSRIs on the other neurotransmitters especially on the glutamate re-
lease are not fully understood.
The effects of SSRIs on presynaptic glutamate release recently
showed that ﬂuoxetine, which is also a SSRI inhibited glutamate re-
lease through the suppression of P/Q-type Ca2+ channel activity in
cerebrocortical nerve terminals [14]. The potential antidepressant
compound LY367265, which was an inhibitor of the serotonin trans-
porter protein, also decreased glutamate release in rat cerebral cortex
[15]. On the contrary, it was also reported that desipramine, a tricyclic
antidepressant, reversibly and concentration-dependently increased
the frequency of spontaneous EPSCs, which suggested that it in-
creased presynaptic glutamate release in locus coeruleus [16]. Anoth-
er research reported that the acute application of the tricyclic
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sis of glutamate in the hippocampus [17]. According to these contra-
dictory results, it was hypothesized that SSRIs might have different
effects and underlying mechanisms on glutamate release in different
brain regions, especially in different conditions of animal.
In order to test the hypothesis, the present study used both control
C57BL/6mice and chronic restraint stress C57BL/6mice, which induced
depression-like behavior [18]. Firstly, the effect of antidepressant
ﬂuvoxamine, which is an effective SSRI on the presynaptic glutamate
release in the pyramidal cells of the layers V–VI of the prelimbic cortex
of control C57BL/6 mice was compared with chronic restraint stress
C57BL/6 mice. The results indicated that the effect of ﬂuvoxamine on
the glutamate release of depressive state mice was different as
compared to control mice. To further understand the mechanisms
underlying the different effects ofﬂuvoxamine, the possible presynaptic
receptors and the signaling pathway using electrophysiological and
biochemical methods combined with pharmacological approaches in
slice and synaptosomes were examined.2. Materials and methods
2.1. Chemicals
Fluvoxamine, BD1047, Xestospongin C, 1-(m-chlorophenyl)-bigua-
nide (CPBG), MDL72222, chelerythrine, (+)-N-allylnormetazocine
(SKF10047), Ethyleneglycol-bis (β-aminoethyl ether) N,N,N′,N′-tetraa-
cetic acid (EGTA), β-Nicotinamide adenine dinucleotide phosphate
(NADP+), L-glutamate dehydrogenase, L-glutamate were purchased
from Sigma-Aldrich (St. Louis, MO). Fluo-3 AM and pluronic F-127
were purchased from Molecular Probes. Percoll was purchased from
Amersham Biosciences Corporation. Other reagents in AR grades were
products of Shanghai Chemical Plant. Fluvoxamine, BD1047, ruanodine,
CPBG, MDL72222, EGTA, NADP+, and L-glutamate were dissolved in
ddH2O and others were dissolved in DMSO. When DMSO was used as
the vehicle, drugswere initially dissolved in 100%DMSO and then dilut-
ed into Hanks' balanced salt solution (HBSS) at a ﬁnal DMSO concentra-
tion of 0.1%, which was conﬁrmed to have no effects on the parameters
to be assessed.2.2. Restraint stress protocol
Adult C57BL/6 male mice weighing 25–30 g, 6 in each experimen-
tal group, were physically restrained for 16 h in a 50-ml polypropyl-
ene centrifuge tube in which holes had been drilled; mice were not
physically squeezed or compressed, and they did not experience
pain. This procedure was believed to create a stressful experience
that was largely psychological in nature due to the conﬁnement of
the animal [19]. In all the studies, to avoid complications due to diur-
nal variation of both hormone production and immune response,
members of all treatment groups were stressed on a given day be-
tween 6 p.m. and 10 a.m. Mice were then carefully removed from
the tubes and placed in their home cage for an additional 10 min be-
fore being sacriﬁced. The mice in control group remained unhandled
in their home cages until being sacriﬁced [20].2.3. Preparation of slices
C57BL/6 mice were anesthetized with chloral hydrate (400 mg/kg,
i.p.). All experimental procedures conformed to international
guidelines on the ethical use of animals, and all efforts were made
to minimize the number of animals used and their suffering. Brain
slices were prepared according to procedures described previously
[21].2.4. Whole-cell recording
The slice was continuously perfused with ACSF saturated with 95%
O2/5% CO2. Electrodes were pulled from glass capillaries using a Nar-
ishige micropipetter puller (model PB-7). They were ﬁlled with a so-
lution containing 140 mM K-gluconate, 0.1 mM CaCl2, 2 mM MgCl2,
1 mM EGTA, 2 mM ATP K2, 0.1 mM GTP Na3 and 10 mM HEPES (pH
7.25) and had a resistance of 4–6 MΩ. Voltage and current signals
were recorded with an Axopatch 200B ampliﬁer (Axon) connected
to a Digidata1200 interface (Axon). The data was digitized and stored
on disks using pClamp (version 6; Axon). Resting membrane poten-
tial and action potentials were recorded under the current clamp
mode. mEPSCs were recorded in sweeps of 2 s at a holding potential
of−70 mV under the voltage clampmode in the presence of tetrodo-
toxin (TTX) (1 mM) and picrotoxin (10 mM). The series resistance
(Rs) was monitored by measuring the instantaneous current in re-
sponse to a 5-mV voltage step command. Series resistance compensa-
tion was not used, but cells where Rs changed by >15% were
discarded.
2.5. Synaptosome preparation
Synaptosomes were prepared as described previously [22]. The
prelimbic cortex was dissected and homogenized in 0.32 M sucrose
solution at 4 °C using the Art-Miccra D-8 tissue grinder with a
motor-driven pestle rotating at 900 rpm. The homogenate was centri-
fuged at 3000 ×g for 3 min at 4 °C. The supernatant (S1) was centri-
fuged at 14,500 ×g for 12 min at 4 °C. The pellet (P2) was
suspended again and loaded onto Percoll gradients, consisting three
layers of 23%, 10%, and 3% Percoll in 0.32 M sucrose additionally con-
taining 1 mM EDTA and 250 μM DTT. The gradients were centrifuged
at 32,500 ×g for 6.5 min at 4 °C. Synaptosomes were harvested from
the interface between the 23% and 10% percoll layers, and washed
in Hanks' balanced salt solution (HBSS) containing 140 mM NaCl,
5 mM KCl, 5 mMNaHCO3, 1 mMMgCl2, 1.2 mMNa2HPO4, 10 mM glu-
cose and 20 mM HEPES, pH 7.4. The washed synaptosomes were cen-
trifuged at 27,000 ×g for 15 min at 4 °C. The protein concentration of
the synaptosomes was determined by the method of Lowry et al. [23]
with the bovine serum albumin as the standard protein.
2.6. Measurement of glutamate release from synaptosomes
Glutamate release was assayed by on-line ﬂuorimetry as described
previously [24]. Synaptosomal pellets were suspended again by add-
ing 1.5 ml of incubation medium: 122 mM NaCL, 3.1 mM KCI,
0.4 mM KH2PO4, 5 mM NaHCO3, 20 mM Na-TES(N-[Tris(hydroxy-
methyl)methyl]-2-aminoethanesulfonic acid), 1.2 mM Mg2SO4,
16 pM bovine serum albumin (fatty acid free, Type V), and 10 mM
D-glucose, pH 7.4. Additionally, NADP+ (2 mM), glutamate dehydro-
genase (50 units/ml) and CaCl2 (1 mM) were added after 3 min.
After incubation of 5 min, 4-aminopyridine (1 mM) or KCl (15 mM)
or ionomycin (5 mM) was added to stimulate glutamate release.
The oxidative decarboxylation of released glutamate, leading to the
reduction of NADP+, was monitored by measuring NADPH ﬂuores-
cence at excitation and emission wavelengths of 340 nm and
460 nm, respectively. Data points were obtained at 60 s intervals. A
standard of exogenous glutamate (5 nmol) was added at the end of
each experiment, and the ﬂuorescence change produced by the addi-
tion of exogenous glutamate (5 nmol) was used to calculate the re-
leased glutamate as nmol/mg.
2.7. Measurement of the intrasynaptosomal Ca2+ concentration
Puriﬁed synaptosomes were loaded with the acetoxymethyl ester
derivative of the calcium-sensitive ﬂuorescent dye Fluo-3 AM
(5.0 μM) for 30 min at 37 °C [25]. After being washed by centrifugation,
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Ca2+ and 0.5 mMMg2+. Aliquots (200 μl) of synaptosomal samples
were put into the 96 well plates with a ﬁnal protein concentration of
200–250 μg/ml. The ﬂuorescence intensity was measured at 527 nm
in response to 485 nm excitation with Thermo Scientiﬁc Fluoroskan
Ascent equippedwith ﬂuorescent analysis system. The Ca2+ concentra-
tion is expressed as the ﬂuorescence ratiometric ΔF/F0%, which reﬂects
a relative, not an absolute measurement of the free Ca2+ concentration
[26].ΔF/F0%=(F−F0)/F0×100,where F is the ﬂuorescence intensity at
each time point and F0 is the ﬂuorescence intensity of the “rest” level
given by the average of ﬂuorescence intensities before adding different
reagent.2.8. Off-line data analysis
Off-line data analysis was performed using a Mini Analysis Pro-
gram (Synaptosoft), SigmaPlot (Jandel Scientiﬁc) and Origin (Micro-
cal Software). Numerical data was expressed as mean±SEM
(standard error of means). Statistical signiﬁcance was determined
using Student's paired t-test for comparisons between two groups
or ANOVA followed by Student–Newman–Keuls test for comparisons
among three or more groups. In all cases ‘n’ refers to the number of
samples (different samples come from different animals) studied.Fig. 1. Effects of ﬂuvoxamine (10 nM) on the glutamate release in the prelimbic cortex of c
records in control and ﬂuvoxamine. Holding potential is −70 mV. B: The cumulative distr
course in a typical cell. D: Averaged frequency of mEPSCs before and after ﬂuvoxamine. E: T
lative distributions of the inter-event intervals of mEPSCs before and after ﬂuvoxamine. G: T
amine. I: The time course of control and the effect of ﬂuvoxamine (10 nM). J: The averaged3. Results
3.1. Fluvoxamine had no effect on the presynaptic glutamate release of
control C57BL/6 mice
To test the effect of ﬂuvoxamine on the presynaptic glutamate re-
lease, the effect of ﬂuvoxamine was observed on the frequency of
mEPSCs in the pyramidal cells of layers V–VI of the prelimbic cortex,
which was considered as a result of the release of glutamate in an ac-
tion potential-independent manner, and had been used as a measure
of modulation of this kind of release [27,28]. Fig. 1A, B, C, D showed
the effect of ﬂuvoxamine (10 nM) on the frequency of mEPSCs in
the slice of prelimbic cortex of control C57BL/6 mice. From the raw
current traces (Fig. 1A), typical records illustrated that the ﬂuvoxa-
mine had no inﬂuence on the frequency of mEPSCs of control
C57BL/6 mice. To demonstrate it in a more accurate manner, cumula-
tive probability plots were constructed with the use of the inter-event
interval distribution of mEPSCs recorded before and after ﬂuvoxa-
mine, and a comparison was made between the distribution in con-
trol and ﬂuvoxamine with K–S test. The result showed that
ﬂuvoxamine (10 nM) had no effects on the cumulative distribution
of the inter-event intervals of mEPSCs (P>0.05, K–S test, Fig. 1B).
The experiment was repeated in six cells and similar results were
obtained. The averaged time course curve also showed that theontrol C57BL/6 mice (A–D) and chronic restraint stress C57BL/6 mice (E–J). A: Typical
ibutions of the inter-event intervals of mEPSCs before and after ﬂuvoxamine. C: Time
ypical records in control and ﬂuvoxamine. Holding potential is−70 mV. F: The cumu-
ime course in a typical cell. H: Averaged frequency of mEPSCs before and after ﬂuvox-
concentration of control and after ﬂuvoxamine.
Fig. 1 (continued).
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was the averaged frequency before and during 4–6 min after ﬂuvox-
amine (2.53±0.71 Hz before and 2.46±0.89 Hz during 4–6 min
after ﬂuvoxamine, n=6), which demonstrated that there was no sta-
tistically signiﬁcant change after ﬂuvoxamine (P>0.05).
The effect of ﬂuvoxamine was studied on the glutamate release from
synaptosomes of prelimbic cortex by on-line ﬂuorimetry. The averaged
concentration of glutamate after ﬂuvoxamine was 9.01±0.84 nmol/mg,
which was not statistically signiﬁcant as compared with the control
value of 8.79±0.78 nmol/mg (n=5, P>0.05).3.2. Fluvoxamine apparently increased glutamate release of chronic
restraint stress C57BL/6 mice
To investigate if ﬂuvoxamine had different effects on the presyn-
aptic glutamate release of chronic restraint stress C57BL/6 mice, and
to investigate the effect of ﬂuvoxamine (10 nM) on presynaptic gluta-
mate release in slices using the frequency of mEPSCs as the index of
presynaptic glutamate release. Fig. 1E was the result in a typical cell,
which showed that ﬂuvoxamine increased the frequency of mEPSCs.
Further plotting of a cumulative distribution of mEPSC intervals and
Fig. 2. Inﬂuence of sigma 1 receptor antagonist/agonist and 5-HT3 receptor antagonist on the ﬂuvoxamine-induced glutamate release in the prelimbic cortex of chronic restraint
stress C57BL/6 mice. A: The time course of the action of BD1047 (1 μM) on the ﬂuvoxamine (10 nM)-induced glutamate release (n=6). B: The averaged results in a group of
cells, there were no signiﬁcant differences between the BD1047 alone group and BD1047+ﬂuvoxamine group, n=6, P>0.05. C: The time course of the effect of SKF10047
(10 μM) on the glutamate release of synaptosomes (n=6). D: The averaged results in a group of cells, there were no signiﬁcant differences between control and SKF10047 groups,
n=6, P>0.05. E: The time course of the action of MDL72222 (30 μM) on the ﬂuvoxamine-induced glutamate release (n=6). F: The averaged results in a group of cells, there were
no signiﬁcant differences between the MDL72222 alone group and MDL72222+ﬂuvoxamine group, n=6, P>0.05.
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a clear shift toward shorter intervals in the cumulative curve (Fig. 1F),
and the shift was statistically signiﬁcant (Pb0.01), indicating that, as
expected from the raw data, there was indeed a substantial increasein the frequency of mEPSCs after ﬂuvoxamine. The experiment was
repeated in ﬁve other cells and a similar effect was observed. All six
cells passed the K–S test with Pb0.01. The averaged time course
curve also showed that ﬂuvoxamine (10 nM) increased the mEPSCs
Fig. 3. Inﬂuence of EGTA (1 mM) on the ﬂuvoxamine (10 nM)-induced glutamate re-
lease in the prelimbic cortex of chronic restraint stress C57BL/6 mice. A: The time
course of the action of EGTA on the ﬂuvoxamine-induced glutamate release (n=6).
B: The averaged results in a group of cells, there were no signiﬁcant differences be-
tween the EGTA alone group and EGTA+ﬂuvoxamine group, n=6, P>0.05.
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pooled six cells increased from 2.12±0.58 Hz before to 4.08±
0.63 Hz after application of ﬂuvoxamine (Fig. 1H, n=6, Pb0.05).
The result showed that ﬂuvoxamine increased the frequency of
mEPSCs.
The results from synaptosomes of prelimbic cortex were con-
ﬁrmed by on-line ﬂuorimetry. As shown in Fig. 1I, ﬂuvoxamine signif-
icantly increased the glutamate release from the synaptosomes of
chronic restraint stress C57BL/6 mice. The concentration of glutamate
increased from 9.74±0.88 nmol/mg to 21.65±3.62 nmol/mg after
application of ﬂuvoxamine (Fig. 1J, n=5, Pb0.05, compared with
control).
3.3. Sigma-1 receptor antagonist inhibited the ﬂuvoxamine-induced glu-
tamate release, while sigma-1 receptor agonist had no effect on the pre-
synaptic glutamate release of chronic restraint stress C57BL/6 mice
Fluvoxamine is an agonist of sigma-1 receptor [29,30]. To study
whether ﬂuvoxamine produced its effect via presynaptic sigma-1 re-
ceptors, the inﬂuence of sigma-1 receptor antagonist BD1047 (1 μM)
[31] was observed on the ﬂuvoxamine-induced glutamate release in
chronic restraint stress C57BL/6 mice. To exclude the inﬂuence of
other neurotransmitters, the glutamate release from synaptosomes
was assayed by ﬂuorometry. The result showed that BD1047 (1 μM)
alone had no effect on glutamate release, but it abolished the
ﬂuvoxamine-induced glutamate release (Fig. 2A, n=6). The averaged
concentration of glutamate after the application of ﬂuvoxamine in the
presence of BD1047 was 9.43±0.94 nmol/mg, which was statistically
signiﬁcant from ﬂuvoxamine alone (21.57±4.78 nmol/mg) (Fig. 2B,
Pb0.05).
The role of sigma-1 receptor in the ﬂuvoxamine-induced gluta-
mate release was investigated by observing the effect of sigma-1 re-
ceptor agonist SKF10047 (10 μM) on the glutamate release of
synaptosomes. As shown in Fig. 2C, SKF10047 had no effect on the
glutamate release of synaptosomes. The averaged concentration of
glutamate after the application of SKF10047 was 10.84±0.95 nmol/
mg, which was not statistically signiﬁcant as compared to the control
(10.79±1.24 nmol/mg) (Fig. 2D, n=6, P>0.05), but was statistically
signiﬁcant as compared to the ﬂuvoxamine (34.41±3.82 nmol/mg)
(Fig. 2D, n=6, Pb0.05). These results suggested that the
ﬂuvoxamine-induced glutamate release was not mediated by sigma-
1 receptors alone.
3.4. 5-HT3 receptor antagonist inhibited the ﬂuvoxamine-induced gluta-
mate release of chronic restraint stress C57BL/6 mice
The effect of the 5-HT3 receptor antagonist MDL72222 (30 μM)
was observed on ﬂuvoxamine-induced glutamate release. The results
showed that in the presence of MDL72222 (30 μM), the ﬂuvoxamine-
induced glutamate release of synaptosomes was also eliminated
(Fig. 2E, n=6). The averaged concentration of glutamate after the ap-
plication of ﬂuvoxamine in the presence of MDL72222 was 13.15±
1.42 nmol/mg, which was statistically signiﬁcant from ﬂuvoxamine
alone (35.90±6.60 nmol/mg) (Fig. 2F, Pb0.05). These results sug-
gested that 5-HT3 receptor may also be involved in the mechanism
of ﬂuvoxamine.
3.5. Ca2+ played an important role in the ﬂuvoxamine-induced gluta-
mate release of chronic restraint stress C57BL/6 mice
To analyze the relationship between 5-HT3 receptor and sigma-1
receptor, the role of Ca2+ was investigated in the ﬂuvoxamine-
induced glutamate release. It has been reported that the 5-HT3 recep-
tor was the only ligand-gated ion channel receptor for serotonin, and
had high calcium permeability on presynaptic nerve terminals [32],
and the intrasynaptosomal Ca2+ might have the downstreampathway of 5-HT3 receptor in the mechanism of ﬂuvoxamine. To
test this hypothesis, the inﬂuence of the removal of extracellular
Ca2+ by the Ca2+-free medium containing EGTA [33] was observed
on the ﬂuvoxamine-induced glutamate release of synaptosomes.
The results showed that the Ca2+-free medium containing EGTA
(1 mM) alone had no effects on the glutamate release of synapto-
somes, but it abolished ﬂuvoxamine-induced glutamate release
(Fig. 3A, n=6). The average concentration of glutamate after the appli-
cation of ﬂuvoxamine in the presence of EGTA was 10.51±1.66 nmol/
mg, which was statistically signiﬁcant from ﬂuvoxamine alone (30.29±
2.37 nmol/mg) (Fig. 3B, Pb0.05). These results conﬁrmed that Ca2+
was one of the important factors in the mechanism of the effect of
ﬂuvoxamine.
3.6. Fluvoxamine elevated Ca2+ concentration by two phases which were
mediated by 5-HT3 receptor and sigma-1 receptor in synaptosomes of
chronic restraint stress C57BL/6 mice
The intrasynaptosomal Ca2+ concentration was monitored to
further investigate the inﬂuence of ﬂuvoxamine on the intrasynapto-
somal Ca2+. The results showed that there were two phases of the el-
evation of Ca2+ concentration. Firstly, ﬂuvoxamine transiently
increased intrasynaptosomal Ca2+ concentration at 4–6 min in the
experiment and then dropped to control level. Then the Ca2+ concen-
tration elevated again after 7 min (Fig. 4A red line). As shown in
Fig. 4. Inﬂuence of sigma 1 receptor antagonist and 5-HT3 receptor antagonist on the ﬂuvoxamine-induced elevation of Ca2+ concentration in the prelimbic cortex of chronic re-
straint stress C57BL/6 mice. A: Time course of the effect of ﬂuvoxamine (10 nM) on the intrasynaptosomal Ca2+ concentration in the synaptosomes from the prelimbic cortex of
animal model of chronic restraint stress and the inﬂuence of MDL72222 (30 μM), BD1047 (1 μM) on the ﬂuvoxamine-induced elevation of Ca2+ concentration (n=6). B: The av-
eraged Ca2+ concentration of phase 1 and phase 2 of the effect of ﬂuvoxamine, *Pb0.05, compared to control, n=6. C: The averaged Ca2+ concentration of phase 1 and phase 2 of
the effect of ﬂuvoxamine in the present of MDL72222, P>0.05, compared to control, n=6. D: The averaged Ca2+ concentration of phase 1 and phase 2 of the effect of ﬂuvoxamine
in the present of BD1047. Phase 1: *Pb0.05; phase 2: P>0.05, compared to control, n=6.
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tion of the ﬁrst phase at 4–6 min was 15.19±2.53%, which was statis-
tically signiﬁcant as compared to the control value of 3.15±1.14%
(n=6, Pb0.05). The average increase in the percentage of the Ca2+
concentration of the second phase at 15–17 min was 32.22±4.23%
(n=6, Pb0.05, compared with control).
To determine whether the elevation of Ca2+ concentration had
the relationship with presynaptic 5-HT3 receptors, the effect of
MDL72222 (30 μM) was observed on ﬂuvoxamine-induced elevation
of Ca2+ concentration. The results showed MDL72222 completely
inhibited the ﬂuvoxamine-induced elevation of Ca2+ concentration
(Fig. 4A green line). As shown in Fig. 4C, the average percentage of
the Ca2+ concentration at 4–6 min was 1.19±0.53%, which was not
statistically signiﬁcant as compared to the control (1.08±0.32%) (n=6,
P>0.05), and the Ca2+ concentration at 15–17 min was 1.45±0.62%,
which was also not statistically signiﬁcant as compared to the control
(n=6, P>0.05). These results suggested that 5-HT3 receptors were the
upstream event of the ﬂuvoxamine-induced elevation of intrasynaptoso-
mal Ca2+.
To examine the possible role of sigma-1 receptors, the effect of
BD1047 was investigated on the ﬂuvoxamine-induced elevation of Ca2+
concentration. The results showed that in the presence of BD1047, thesecond phase of the elevation of intrasynaptosomal Ca2+ concentration
was inhibited. However, BD1047 had no effect on the ﬁrst phase
(Fig. 4A blue line). As shown in Fig. 4D, the average percentage of the
Ca2+ concentration at 4–6 minwas 12.42±1.35%, whichwas statistically
signiﬁcant as compared to the control (3.45±0.98%) (n=6, Pb0.05). The
Ca2+ concentration at 15–17 minwas 2.34±1.24% (n=6, P>0.05, com-
paredwith control). These results suggested that sigma-1 receptorsmight
be the downstream pathway of 5-HT3 receptors-mediated elevation of
Ca2+ concentration.
3.7. The endoplasmic reticulum calcium channel blocker inhibited the
second phase of the ﬂuvoxamine-induced elevation of Ca2+ concentra-
tion and abolished the ﬂuvoxamine-induced glutamate release
To investigate the source of the second phase of ﬂuvoxamine-
induced elevation of intrasynaptosomal Ca2+ concentration, the inﬂu-
ence of the endoplasmic reticulum calcium channel (IP3 receptor)
blocker xestospongin C (25 μM) [34] was observed on the ﬂuvoxamine.
Xestospongin C alone had no effect on intrasynaptosomal Ca2+ concen-
tration (n=6, P>0.05, data not shown). However, it completely
blocked the second phase of the ﬂuvoxamine-induced elevation of
Ca2+ concentration (Fig. 5A), suggesting that the intracellular calcium
Fig. 5. Inﬂuence of Xestospongin C (25 μM) on the ﬂuvoxamine (10 nM)-induced elevation of Ca2+ concentration and ﬂuvoxamine-induced glutamate release in the prelimbic cor-
tex of chronic restraint stress C57BL/6 mice. A: Time course of the inﬂuence of Xestospongin C (25 μM) on the ﬂuvoxamine-induced elevation of Ca2+ concentration (n=6). B: The
averaged Ca2+ concentration of phase 1 and phase 2 of the effect of ﬂuvoxamine in the present of Xestospongin C. Phase 1: *Pb0.05; phase 2: P>0.05, compared to control, n=6. C:
The time course of the action of Xestospongin C on the ﬂuvoxamine-induced glutamate release. D: The averaged results in a group of cells, there were no signiﬁcant differences
between the Xestospongin C alone group and Xestospongin C+ﬂuvoxamine group, n=6, P>0.05.
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the ﬂuvoxamine-induced elevation of intrasynaptosomal Ca2+ concen-
tration. As shown in Fig. 5B, the average percentage of the Ca2+ concen-
tration at 4–6 minwas 11.16±0.26%, whichwas statistically signiﬁcant
as compared to the control (1.53±0.05%) (n=6, Pb0.05) and the Ca2+
concentration at 15–17 min was 2.48±0.09% (n=6, P>0.05, com-
pared with control).
The inﬂuence of Xestospongin C on the ﬂuvoxamine-induced glu-
tamate release was tested. The results showed that Xestospongin C
completely inhibited the ﬂuvoxamine-induced glutamate release of
synaptosomes, which conﬁrmed that the intrasynaptosomal Ca2+ re-
leased from the endoplasmic reticulum might have an effect on ﬂu-
voxamine and glutamate release (Fig. 5C, n=6). In the presence of
Xestospongin C, the average concentration of glutamate after the ap-
plication of ﬂuvoxamine was 9.07±0.44 nmol/mg, which was not
statistically signiﬁcant as compared to the control (9.69±
0.61 nmol/mg) (Fig. 5D, P>0.05).
3.8. PKC played a key role in the ﬂuvoxamine-induced glutamate release
in synaptosomes of chronic restraint stress C57BL/6 mice
PKC was activated by Ca2+ and DAG. To investigate the down-
stream event of the intrasynaptosomal Ca2+ released from the endo-
plasmic reticulum, the effect of PKC inhibitor chelerythrine (2.5 μM)
was observed on the ﬂuvoxamine-induced glutamate release. Theresults showed that chelerythrine alone had no effect on the gluta-
mate release, but it inhibited ﬂuvoxamine-induced glutamate release
(Fig. 6A, n=6), which suggested that PKC may also have a key role to
play on the effect of ﬂuvoxamine. The average concentration of gluta-
mate after the application of ﬂuvoxamine in the presence of cheler-
ythrine was 8.47±0.16 nmol/mg, which was not statistically
signiﬁcant as compared to control (8.00±0.65 nmol/mg) (Fig. 6B,
P>0.05).
3.9. Sigma-1 receptor agonist increased the glutamate release in the pre-
sent of 5-HT3 receptor agonist in synaptosomes of chronic restraint stress
C57BL/6 mice
To investigate the possible synergistic effect of sigma-1 receptor
and 5-HT3 receptors in chronic restraint stress mice, the effect of
SKF10047 was observed on the glutamate release in the presence of
CPBG. The results showed that CPBG 3 μM increased glutamate re-
lease, however, SKF10047 10 μM ampliﬁed the effect of CPBG signiﬁ-
cantly (Fig. 7A, n=4). The average concentration of glutamate after
the application of SKF10047 in the presence of CPBG was 26.54±
3.81 nmol/mg, which was statistically signiﬁcant as compared to
CPBG alone (15.65±1.78 nmol/mg) (Fig. 7B, Pb0.05). The average
concentration of CPBG+SKF10047 group was not statistically signif-
icant as compared to ﬂuvoxamine (27.11±4.91 nmol/mg) (Fig. 7B,
P>0.05).
Fig. 6. Inﬂuence of chelerythrine (2.5 μM) on the ﬂuvoxamine (10 nM)-induced gluta-
mate release in the prelimbic cortex of chronic restraint stress C57BL/6 mice. A: The
time course of the action of chelerythrine on the ﬂuvoxamine-induced glutamate re-
lease (n=6). B: The averaged results in a group of cells, there were no signiﬁcant dif-
ferences between the chelerythrine alone group and chelerythrine+ﬂuvoxamine
group, n=6, P>0.05.
Fig. 7. SKF10047 could amplify the effect of CPBG (3 μM) on the glutamate release in
the prelimbic cortex of chronic restraint stress C57BL/6 mice. A: The time course of
the effect of SKF10047, CPBG, CPBG+SKF10047 and ﬂuvoxamine on the glutamate re-
lease (n=4). B: The averaged results in a group of cells, SKF10047 (10 μM) alone
group had no signiﬁcant effect on the glutamate, P>0.05, compared to control,
n=4; CPBG alone group, CPBG+SKF10047 group and ﬂuvoxamine group could in-
crease the glutamate release signiﬁcantly, *Pb0.05, compared to control, n=4;
SKF10047 could amplify the effect of CPBG signiﬁcantly, #Pb0.05, compared to the
CPBG group. Fluvoxamine could increase the glutamate release signiﬁcantly,
##Pb0.05, compared to the CPBG group.
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5-HT3 receptor agonist in synaptosomes of control C57BL/6 mice
To investigate the different mechanisms between control C57BL/6
mice and chronic restraint stress C57BL/6 mice, the effect of ﬂuvoxa-
mine was noted on the glutamate release in the present of 5-HT3 re-
ceptors agonist CPBG by using control C57BL/6 mice. The results
showed that CPBG 3 μM increased glutamate release, however, ﬂu-
voxamine ampliﬁed the effect of CPBG signiﬁcantly (Fig. 8A, n=6).
The average concentration of glutamate after the application of ﬂu-
voxamine in the presence of CPBG was 18.19±1.45 nmol/mg,
which was statistically signiﬁcant as compared to CPBG alone
(11.11±0.76 nmol/mg) (Fig. 8B, Pb0.05). The percentage increase
of CPBG+ﬂuvoxamine group (121.86±20.29%) was signiﬁcantly
higher than CPBG alone (60.41±10.74%) (Fig. 8C, n=6, Pb0.05).
4. Discussion
Previous studies indicated that the effects of SSRIs treatment
might be linked with glutamatergic transmission [35]. The present
study found that ﬂuvoxamine which is one of the SSRIs increased
the presynaptic glutamate release in animal model of chronic re-
straint stress, but had no effect on control. The mechanisms that
shaped presynaptic signals and glutamate release in response to theﬂuvoxamine were identiﬁed. These ﬁndings suggested that ﬂuvoxa-
mine might have the selective action and different mechanisms on
presynaptic glutamate release between chronic restraint stress mice
and control mice.
Because ﬂuvoxamine had been reported to be effective in improv-
ing cognitive impairments [30], and the prelimbic regions of the cere-
bral cortex were expected to be particularly associated with cognitive
abnormalities that were seen in many patients with depression, in the
present experiment, the effect of ﬂuvoxamine was observed on the
presynaptic glutamate release in the pyramidal cells of layers V–VI
of the prelimbic cortex. The effect of ﬂuvoxamine was studied by
using both control C57BL/6 mice and chronic restraint stress C57BL/
6 mice.
It has been known that the selective serotonin reuptake inhibitor
(SSRI) ﬂuvoxamine is also a very potent agonist at sigma-1 receptors
[36]. The evidence suggests that sigma-1 receptors, which are intra-
cellular endoplasmic reticulum (ER) proteins, and are involved in
both the neuroplasticity and pathophysiology of depressive disorder
[37,38]. It is possible that the mechanism underlying the effect of ﬂu-
voxamine in chronic restraint stress C57BL/6 mice may involve pre-
synaptic sigma-1 receptors. The hypothesis was supported by the
Fig. 9. Schematic representation of the possible mechanism underlying the effect of ﬂu-
voxamine on presynaptic glutamate release in prelimbic cortex of animal model of
chronic restraint stress. Fluvoxamine could increase presynaptic glutamate release by
activating presyanaptic 5-HT3 receptors and lead to the ﬁrst phase of the elevation of
Ca2+ concentration (blue line). And the transient elevation of Ca2+ concentration
may be an important factor which could activate sigma-1 receptors. And then ﬂuvoxa-
mine could activate the presynaptic sigma-1 receptors to increase the intrasynaptoso-
mal Ca2+ concentration signiﬁcantly through the outﬂow of endoplasmic reticulum
calcium and activate PKC to increase the glutamate release (red line).
Fig. 8. Fluvoxamine could amplify the effect of CPBG (3 μM) on the glutamate release in
the prelimbic cortex of control C57BL/6 mice. A: The time course of the effect of ﬂuvoxa-
mine, CPBG and CPBG+ﬂuvoxamine on the glutamate release (n=6). B: The averaged
results in a group of cells, ﬂuvoxamine alone group had no signiﬁcant effect on the gluta-
mate, P>0.05, compared to control, n=6; CPBG alone group and CPBG+ﬂuvoxamine
group could increase the glutamate release signiﬁcantly, *Pb0.05, compared to control,
n=6; C: ﬂuvoxamine could amplify the effect of CPBG signiﬁcantly, #Pb0.05, compared
to the CPBG group.
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onist of sigma-1 receptors, could completely inhibit the effect of ﬂu-
voxamine on the glutamate release in prelimbic cortex of chronic
restraint stress C57BL/6 mice, but the sigma-1 receptor agonistSKF10047 had no effect on the presynaptic glutamate release. The
biochemical experiments by Morin-Surun, M.P, suggested that the
sigma-1 receptor was an intracellular protein anchored on the endo-
plasmic reticulum, and the activation of sigma-1 receptor from the
cytoplasm to the membrane required the agonist of sigma-1 receptor
[39]. It was possible that in the prelimbic cortex of chronic restraint
stress C57BL/6 mice, the mechanism of the effect of ﬂuvoxamine
was more complicated. In addition to sigma-1 receptors agonist,
there might be other approaches to activate the sigma-1 receptors.
Based on the reports that ﬂuvoxamine might also activate 5-HT3 re-
ceptors [40], in the experiment, the role of presynaptic 5-HT3 recep-
tors was investigated by using MDL72222, an antagonist of 5-HT3
receptors. The results showed that MDL72222 could completely in-
hibit the increased effect of ﬂuvoxamine on glutamate release in the
prelimbic cortex of chronic restraint stress C57BL/6 mice. Considering
that there was no 5-HT or other agonist of 5-HT3 receptor in the syn-
aptosomes sample, except ﬂuvoxamine no other 5-HT3 receptors
could activate other agonist. This result suggested that presynaptic
5-HT3 receptors might also be involved in the mechanism of ﬂuvoxa-
mine effect. This was the ﬁrst report, which suggested that ﬂuvoxa-
mine activated 5-HT3 receptors in the brain.
The 5-HT3 receptor is the only ligand-gated ion channel receptor
for serotonin and it has high calcium permeability on presynaptic
nerve terminals [32]. The downstream signal transduction pathways
of the activation of 5-HT3 receptors by ﬂuvoxamine might be mediat-
ed by extrasynaptosomal Ca2+ inﬂux through 5-HT3 receptors. In the
experiment, the extracellular Ca2+ was removed from the Ca2+-free
medium containing EGTA, and the result showed that the
ﬂuvoxamine-induced glutamate release disappeared. This result con-
ﬁrmed the hypothesis and suggested that 5-HT3 receptors-induced
Ca2+ inﬂux might be another important factor of the activation of
sigma-1 receptors from the cytoplasm to the membrane.
To determine the relationship between 5-HT3 receptor and sigma-
1 receptor, the effect of ﬂuvoxamine on intrasynaptosomal Ca2+ con-
centration was monitored. The results showed that the ﬂuvoxamine-
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phases. 5-HT3 receptors antagonist abolished the increase of intrasy-
naptosomal Ca2+, which conﬁrmed that ﬂuvoxamine-induced gluta-
mate release was ﬁrstly mediated by 5-HT3 receptors-induced
increase of intrasynaptosomal Ca2+. The results also suggested that
5-HT3 receptors were at the upstream of the effect of ﬂuvoxamine.
The following experiment found that the sigma-1 receptor antag-
onist abolished the second phase of the ﬂuvoxamine-induced Ca2+
elevation, but it had no inﬂuence on the ﬁrst phase. The endoplasmic
reticulum calcium release channel blocker had the same effect on the
ﬂuvoxamine-induced Ca2+ elevation and it also inhibited the
ﬂuvoxamine-induced glutamate release completely. Considering
that the sigma-1 receptors coupled with Gq protein to generate IP3,
which increased intrasynaptosomal Ca2+ by activating IP3 receptors
in endoplasmic reticulum [41], these results suggested that the sec-
ond phase of the ﬂuvoxamine-induced elevation of Ca2+ was mediat-
ed by sigma-1 receptors through the outﬂow of endoplasmic
reticulum calcium.
It has been known that the downstream pathway of the sigma-1
receptors involved the activation of PKC by DAG and endoplasmic re-
ticulum calcium release, and PKC might also be involved in the
ﬂuvoxamine-induced glutamate release. The hypothesis was tested
by observing the inﬂuence of PKC inhibitor on the ﬂuvoxamine-
induced glutamate release, which conﬁrmed that PKC was the down-
stream pathway of the effect of ﬂuvoxamine.
However, these results remained unclear as ﬂuvoxamine had no
effect on the glutamate release of control C57BL/6 mice. As the results
suggested, ﬂuvoxamine activated 5-HT3 receptors ﬁrstly to increase
the glutamate release in chronic restraint stress C57BL/6 mice, so it
was possible that ﬂuvoxamine has no effect on 5-HT3 receptor in con-
trol mice. To test the hypothesis, the effect of ﬂuvoxamine was ob-
served in the presence of 5-HT3 receptor agonist CPBG. The results
showed that CPBG increased the presynaptic glutamate release,
which was consistent with the previous report [42]. However, it
also showed that ﬂuvoxamine ampliﬁed and increased the effect of
CPBG signiﬁcantly, which suggested that ﬂuvoxamine increased the
glutamate release when there was activation of 5-HT3 receptors in
control C57BL/6 mice. These results demonstrated that the different
effects of ﬂuvoxamine on the presynaptic glutamate release were
due to the different actions of ﬂuvoxamine on presynaptic 5-HT3 re-
ceptors. In control mice, ﬂuvoxamine had no effect on 5-HT3 recep-
tors. However, in the chronic restraint stress mice, ﬂuvoxamine
activated 5-HT3 receptors. This effect of ﬂuvoxamine on 5-HT3 recep-
tors might be due to the increased amount of 5-HT3 receptor expres-
sion in synaptosomes of restraint stress C57BL/6 mice (Fig.10 sup),
which was as a result of the decrease of the extrasynaptic 5-HT3 con-
centration in depression state.
Hence, it was concluded that ﬂuvoxamine had different effects on
the presynaptic glutamate release between control C57BL/6 mice and
depression mice. This was due to the different actions of ﬂuvoxamine
on presynaptic 5-HT3 receptors. In chronic restraint stress C57BL/6
mice, ﬂuvoxamine increased presynaptic glutamate release by acti-
vating presynaptic 5-HT3 receptors and led to the ﬁrst phase of the el-
evation of Ca2+ concentration, and then ﬂuvoxamine activated the
presynaptic sigma-1 receptors to increase the intrasynaptosomal
Ca2+ concentration signiﬁcantly through the outﬂow of endoplasmic
reticulum calcium and activate PKC (Fig. 9).
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